Overview

Ustekinumab for the Treatment of Giant Cell Arteritis

Status:
Terminated
Trial end date:
2019-09-19
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether ustekinumab is effective in the treatment of Giant Cell Arteritis (GCA)
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Massachusetts General Hospital
Treatments:
Prednisone
Ustekinumab